trial

CARE Study: Improving Treatment for the Most Severely Ill With Schizophrenia

NCTId NCT00272584
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 4 · Completed
Enrollment 100
Sponsored by University of British Columbia
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 4
Status
Completed
Enrollment
100
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2001-06
Primary completion
—
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Risperidone

Sponsors

University of British ColumbiaLead Sponsor

Investigators

1
William G Honer, ProfessorPrincipal Investigator

Sites

1 total
Vancouver, Canada

Facts & assertions

3 sourced
Enrollment
100
Phase
PHASE4
Status
COMPLETED
relationships
The graph out of here
drug
Risperidone
drug
lead_sponsor
University of British Columbia
company
indication
Schizophrenia
indication
Psychosis, Schizophrenia
indication
Psychotic Disorders
indication
investigator
William G Honer, Professor
person